<DOC>
	<DOCNO>NCT01444001</DOCNO>
	<brief_summary>This study design evaluate safety , tolerability , immunogenicity three dose investigational pneumococcal vaccine healthy adult volunteer . Primary Objective : - To evaluate safety tolerability investigational Pneumococcal vaccine .</brief_summary>
	<brief_title>Study Investigational Pneumococcal Vaccine Healthy Adult Volunteers</brief_title>
	<detailed_description>Each volunteer participant receive two injection one three vaccine dos , administer Day 0 Day 30 , dose-ascending manner , pending safety review dose level . All participant monitor safety 30 day injection .</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Pneumonia , Pneumococcal</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Aged 18 50 year day inclusion Healthy , determine medical history clinical examination Informed consent obtain Able attend schedule visit comply trial procedure For woman , inability bear child negative urine pregnancy test vaccination visit For woman childbearing potential : use two medically acceptable , effective method contraception ( oral contraceptive , intrauterine device , diaphragm , spermicide , condom ) abstinence throughout study participation start least 30 day prior first vaccination least 30 day last vaccination . Serious chronic disease ( i.e. , cardiac , renal , neurologic , rheumatologic , metabolic , gastrointestinal , psychiatric , organ system ) could interfere trial conduct and/or raise safety concern For woman , breastfeed Participation another clinical trial 30 day precede first trial vaccination Planned participation another clinical trial present trial period Congenital acquire immunodeficiency , immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month , longterm systemic corticosteroid therapy Systemic hypersensitivity vaccine component history lifethreatening reaction trial vaccine vaccine contain substance Current abuse alcohol drug addiction may interfere subject 's ability comply trial procedure Blood bloodderived product receive past 3 month Any vaccination 30 day precede first trial vaccination Vaccination plan 30 day follow trial vaccination Known Human Immunodeficiency Virus ( HIV ) , hepatitis B , hepatitis C seropositivity Known thrombocytopenia bleed disorder contraindicate intramuscular ( IM ) vaccination Subject deprive freedom administrative court order , emergency setting , hospitalize without his/her consent Febrile illness ( ≥ 38.0°C [ 100.4°F ] ) within 72 hour inclusion/vaccination Previous vaccination precede 5 year pneumococcal disease another vaccine History pneumococcal infection ( confirm either clinically , serologically , microbiologically ) within 5 year Subject high risk pneumococcal infection trial Subjects living household child &lt; 5 year age Antibiotic usage upper low respiratory tract infection within one week blood draw immunogenicity ( Visits 1 , 3 , 5 ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Pneumococcal Infections</keyword>
	<keyword>Pneumococcal Vaccines</keyword>
	<keyword>pneumococcal protein</keyword>
</DOC>